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ABSTRACT 
 
The JAK2V617F mutation is found in most patients with a myeloproliferative 
neoplasm (MPN). This gain-of-function mutation dysregulates cytokine signaling and 
is associated with increased accumulation of DNA damage, a process likely to drive 
disease evolution. JAK2V617F inhibits NHE-1 upregulation in response to DNA 
damage and consequently represses Bcl-xL deamidation and apoptosis, thus giving 
rise to inappropriate cell survival. However, the mechanism whereby NHE-1 
expression is inhibited by JAK2V617F is unknown.  In this study we demonstrate that 
accumulation of reactive oxygen species (ROS) in cells expressing JAK2V617F 
compromises the NHE-1/Bcl-xL deamidation pathway by repressing NHE-1 
upregulation in response to DNA damage. In JAK2V617F-positive cells, increased 
ROS levels results from aberrant PI3K signaling, which decreases nuclear 
localization of FOXO3A and decreases catalase expression.  Furthermore, when 
compared to autologous control erythroblasts, clonally-derived JAK2V617F-positive 
erythroblasts from MPN patients displayed increased ROS levels and reduced 
nuclear FOXO3A. However, in hematopoietic stem cells (HSCs), FOXO3A is largely 
localized within the nuclei despite the presence of JAK2V617F mutation, suggesting 
that JAK2-FOXO signaling has a different effect on progenitors compared to stem 
cells.  Inactivation of FOXO proteins and elevation of intracellular ROS are 
characteristics common to many cancers, and so these findings are likely to be of 
relevance beyond the MPN field.  
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INTRODUCTION 
 
Forkhead box O (FOXO) transcription factors are evolutionarily conserved proteins 
involved in multiple physiological and pathological processes.1  In mammals, three 
principle members of the FOXO subfamily (FOXO1, FOXO3A, FOXO4) are 
abundantly expressed in most tissues, where they promote cell cycle arrest, DNA 
repair, apoptosis, or detoxification of reactive oxygen species (ROS). In particular, 
FOXO3A has been shown to have an important role in hematopoiesis.2-5  The 
function of FOXO proteins is largely regulated by post-translational modifications, the 
main example of which is serine/threonine phosphorylation downstream of the 
PI3K/AKT signaling pathway.1  Phosphorylated FOXO factors are exported from the 
nucleus to the cytoplasm and are targeted for proteasomal degradation. This 
regulation of FOXO proteins is disrupted in several tumor types including breast 
cancer, prostate cancer, glioblastoma, and chronic myeloid leukemia (CML).6  
 
One of the major functions of FOXO proteins is to modulate ROS homeostasis by 
transcriptionally activating ROS detoxifying enzymes such as catalase and SOD.1 
Maintenance of appropriate levels of intracellular ROS is vital for signaling networks, 
which mediate multiple physiological processes.7 In several malignancies, 
perturbation of physiological ROS levels has been found to induce proliferation,8 
amplify survival signalling,9,10 and limit anti-tumor cytotoxicity of various therapeutic 
agents,11-13 therefore contributing to maintenance and progression of the cancer 
phenotype. Increased ROS is also a major cause of DNA damage, which leads to 
chromosomal abnormalities and genome instability.14 Regulation of ROS 
homeostasis by FOXO may therefore play a significant role in limiting cancer 
development and progression.  
 
The myeloproliferative neoplasms (MPNs) are hematological malignances associated 
with overproduction of mature, functional blood cells.15 These diseases are 
characterized by a chronic clinical course together with a risk of transformation to 
AML. In the majority of MPN patients, an acquired gain-of-function mutation (V617F) 
is found in JAK2, a cytoplasmic tyrosine kinase involved in signaling from multiple 
cytokine receptors. Cells expressing JAK2V617F harbor more DNA damage,16-19 and 
of particular note, the JAK2V617F mutation interferes with the normal apoptotic 
response to DNA damage,20,21 thus providing a mechanism for accumulation of DNA 
damage. In normal cells, DNA damage upregulates the Na+/H+ antiport NHE-1, 
thereby increasing intracellular pH, which in turn increases Bcl-xL deamidation and 
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promotes apoptosis. This pathway is inhibited by JAK2V617F in primary cells derived 
from MPN patients, thus permitting increased cell survival despite the presence of 
increased DNA damage21. However, the mechanism by which JAK2V617F inhibits 
NHE-1 upregulation remains unknown.   
 
Here we demonstrate that JAK2V617F-mediated PI3K signaling inactivate FOXO3A 
in both JAK2V617F-expressing cell lines and hematopoietic progenitors from MPN 
patients and knock-in mice.  We show that FOXO3A inactivation associates with 
increased intracellular ROS levels which in turn blocks the NHE-1/Bcl-xL pathway 
and therefore contributes to increased survival of JAK2V617F-expressing cells 
following DNA damage. These findings reveal a mechanism whereby JAK2V617F 
disrupts ROS homeostasis and reduces the normal apoptotic response to DNA 
damage. Finally, using hematopoietic stem cells (HSCs) and progenitors isolated 
from MPN patients and the JAK2V617F knock-in mice,22 we also demonstrate that 
FOXO3A activity downstream of JAK2V617F is distinct in HSCs compared to 
progenitors and more differentiated cells.   
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RESULTS 
 
JAK2V617F elevates intracellular ROS levels and increases survival of 
JAK2V617F-positive cells following DNA damage 
Elevated ROS can contribute to altered signal transduction as well as to 
transformation by a number of oncogenes. We therefore initially investigated the 
effect of JAK2V617F on intracellular ROS, using a cell-permeable fluorescent dye in 
IL3 or Epo-dependent Ba/F3-EpoR cells expressing wild-type JAK2 or the 
constitutively active JAK2V617F. Cells carrying JAK2V617F had higher levels of 
ROS compared to those cells expressing wild-type JAK2 (Figure 1A). We also 
examined the effect of endogenous JAK2V617F on ROS levels by using human 
erythroleukemia (HEL) cells, which harbors multiple copies of mutant JAK2.23 
Following the knockdown of JAK2V617F with siRNA (Supplementary Figure S1A), 
ROS levels were reduced compared to the cells transfected with a control siRNA 
(Figure 1B). Furthermore, treatment of HEL cells with the selective JAK2 inhibitor 
TG101209 also reduced ROS (Supplementary Figure S1B). Together these data 
indicate that exogenous and endogenous JAK2V617F are both associated with 
increased ROS levels. 
 
As ROS levels modulate drug sensitivity in some cancers, we then determined the 
effects of elevated ROS on DNA damage-induced apoptosis. Following treatment 
with the DNA damage-inducing agent etoposide, Ba/F3-EpoR cells carrying 
JAK2V617F had reduced apoptosis compared to cells expressing wild-type Jak2 
(Figure 1C). In addition, knockdown of endogenous JAK2V617F in HEL cells 
increased the sensitivity of these cells to etoposide treatment compared to the cells 
transfected with a control siRNA (Figure 1D). These data demonstrate that 
JAK2V617F increases cell survival following DNA damage.  
 
JAK2V617F-induced increase in ROS mediates cell survival by inhibiting the 
NHE-1/Bcl-xL deamidation pathway 
To determine if elevated ROS levels in JAK2V617F-positive cells directly contribute 
to increased survival following DNA damage, we used MitoQ, a potent antioxidant 
compound targeted specifically to mitochondria to reduce ROS levels (Figure 2A, 
Supplementary Figure S2A). Treatment of HEL or Ba/F3-EpoR cells with etoposide in 
the presence of MitoQ triggered significantly more cell death at all MitoQ 
concentrations tested compared to treatment with etoposide alone (Figure 2B, 
Supplementary Figure S2B). To confirm our results, we also expressed catalase in 
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HEL cells to reduce intracellular ROS levels. Compared to HEL cells transfected with 
a control construct, those transfected with a catalase expression vector showed an 
increase in catalase levels (Figure 2C), a small but significant reduction in ROS 
levels (Figure 2D) and increased apoptosis in response to etoposide (Figure 2E). 
Together these results indicate that elevated ROS levels induced by JAK2V617F 
contribute to increased survival of mutant cells following DNA damage.   
 
Since elevated H2O2 levels have been shown to suppress both NHE-1 promoter 
activity and protein expression in non-hematopoietic cells,24-26 we investigated the 
possibility that the JAK2V617F-mediated increase in ROS levels might modulate the 
response of the NHE-1/Bcl-xL pathway to DNA damage. Cells with wild-type JAK2 
normally respond to DNA damage by increasing NHE-1 expression, Bcl-xL 
deamidation leading to apoptosis, but these effects are abrogated by the presence of 
the JAK2V617F mutation.18,19 Consistent with these data, treatment with etoposide 
alone did not induce an increase in NHE-1 expression or Bcl-xL deamidation in 
JAK2V617F-positive HEL cells (Figure 2F-G). However, following catalase 
expression, the normal response to etoposide treatment was restored with induction 
of both NHE-1 upregulation and Bcl-xL deamidation (Figure 2F-G). These results 
demonstrate that reversing the JAK2V617F-mediated increase in ROS levels 
restores the response of NHE-1/Bcl-xL pathway to DNA damage. 
 
JAK2V617F signaling reduces catalase expression and increases both 
phosphorylation and cytoplasmic sequestration of FOXO3A   
As catalase is one of the main ROS detoxifying enzymes in vivo,27 we next 
investigated the effect of JAK2V617F on endogenous catalase levels.  Catalase 
expression was shown to be increased in HEL cells by either of two selective JAK2 
inhibitors (Figure 3A) and also by siRNA knockdown of JAK2 (Figure 3B).  Moreover, 
catalase expression was lower in Ba/F3-EpoR cells carrying JAK2V617F compared 
to the cells with wild-type JAK2 (Figure 3C). Unlike catalase, both Glutathione 
reductase and SOD2	   expression	   was	   not	   increased	   in	   HEL	   cells	   treated	   with	   JAK2	  
inhibitor,	   but	   rather	   a	   reduction	   of	   SOD2	   expression	   was	   observed.	   	   These	   data	  
suggest	   that	   neither	  Glutathione reductase nor SOD2	   is	   responsible	   for	   JAK2V617F	  
induced	  ROS	  increase	  in	  this	  context	  and	  that	  the	  reduction	  of	  SOD2	  expression	  may	  
be	  a	  consequence	  of	  lowered	  ROS	  in	  the	  presence	  of	  JAK2	  inhibitor	  (Supplementary 
Figure S3).	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Since catalase expression is regulated by FOXO transcription factors,1,5 we next 
examined the possible role of JAK2V617F in modulating transcriptional activity of 
FOXO3A, the abnormal repression or deletion of which has been linked to 
hematological malignancies.28-30 In HEL cells, ser253 phosphorylation of FOXO3A 
was reduced by inhibiting JAK2V617F (Supplementary Figure S4A), indicating that 
JAK2V617F signaling leads to FOXO3A phosphorylation. Since the serine 
phosphorylation inactivates FOXO3A by excluding the protein from the nucleus and 
increasing its cytoplasmic sequestration,31 we investigated the sub-cellular 
localization of FOXO3A by immunofluorescence in HEL cells using an antibody to 
total FOXO3A. Nuclear localization of FOXO3A was significantly increased by two 
different JAK2 inhibitors (Supplementary Figure S4B) and also by siRNA-mediated 
JAK2 knockdown (Figure 3D). Furthermore, in Ba/F3-EpoR cells nuclear localization 
of FOXO3A was reduced by expression of JAK2V617F (Figure 3E) or by a JAK2 
exon12 mutation, K539L (Supplementary Figure S5), but not by expression of 
wildtype JAK2. 
 
Taken together these results demonstrate that JAK2V617F increases 
phosphorylation and cytoplasmic sequestration of FOXO3A, and that this is 
consequently associated with a reduction in catalase expression and an increase in 
intracellular ROS levels.  
 
Inactivation of FOXO3A by JAK2V617F is mediated by PI3K signaling  
In order to study the mechanism whereby FOXO3A is phosphorylated and 
inactivated downstream of JAK2V617F, we focused on the PI3K signaling pathway. 
This pathway is activated in JAK2V617F-positive cells32-34 and has been reported to 
phosphorylate FOXO transcription factors in various cell types.1,28,31 Treatment of 
HEL cells with either of two different PI3K inhibitors resulted in a significant increase 
in nuclear FOXO3A (Figure 4A). Inhibition of PI3K also increased catalase levels 
(Figure 4B), reduced intracellular ROS levels (Figure 4C) and increased etoposide-
induced apoptosis (Figure 4D, E). To investigate whether the increased apoptosis by 
PI3K inhibition was due to reduced ROS, apoptosis was analysed on cells treated 
with sodium azide, an irreversible inhibitor of catalase.  The data indicate that an 
increase in etoposide-induced apoptosis by PI3K inhibition was reversed in the 
presence of sodium azide (Figure 4D, E), thus demonstrating that sensitization to 
DNA damage by PI3K inhibition is dependent on reduced ROS. Together, these data 
indicate that inactivation of FOXO3A by JAK2V617F is mediated by PI3K signaling.  
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Nuclear localization of FOXO3A is reduced in clonally-derived JAK2V617F-
positive erythroblasts from patients with a myeloproliferative neoplasm 
The results described above demonstrate that JAK2V617F reduces nuclear 
localization of FOXO3A and increases ROS in cell lines. We next sought to 
determine if this is also true in primary cells from patients with JAK2V617F-positive 
MPNs. To this end, we studied 419 peripheral blood BFU-E colonies obtained from 3 
patients with JAK2V617F-positive essential thrombocythemia (ET) or polycythemia 
vera (PV). Individual colonies were picked, genotyped for JAK2 mutation status and 
analyzed for FOXO3A localization and intracellular ROS levels. As both wild-type and 
mutant colonies were grown under identical conditions, this experimental strategy 
allowed a direct comparison of JAK2 wild-type and JAK2V617F-positive erythroblasts 
from the same patient.  
 
In each patient, cells carrying the JAK2V617F mutation showed a significant 
reduction in the nuclear localization of FOXO3A compared to those with wild-type 
JAK2 (Figure 5A, B). From one of the PV patients, we obtained both JAK2V617F 
heterozygous and homozygous BFU-E colonies (Figure 5B, Patient 3) and observed 
a further reduction of nuclear FOXO3A in the homozygous cells compared to 
heterozygous cells.  It seems that in this patient that dosage of mutant JAK2 
signaling correlates the extent of FOXO3A cytoplasmic sequestration. In addition, 
ROS levels analyzed in 5 MPN patients were significantly higher in the erythroblasts 
from mutant BFU-E colonies compared to those from wild-type colonies (Figure 5C). 
These results are consistent with our cell line data and demonstrate that, in 
erythroblasts from MPN patients, the JAK2V617F mutation is also associated with 
increased cytoplasmic sequestration of FOXO3A and elevated ROS levels. 
 
Nuclear localization of FOXO3A is not reduced by JAK2V617F in hematopoietic 
stem and early progenitor cells 
We next studied HSCs to determine whether JAK2V617F also results in cytoplasmic 
sequestration of FOXO3A in HSCs. To this end we utilized JAK2V617F knock-in 
mice which carry human JAK2V617F and have a PV-like phenotype.22  In accord with 
our data from human erythroblasts, levels of nuclear FOXO3A were reduced in JAK2 
mutant progenitors (CD150-CD48+CD45+) compared to littermate controls (Figure 6A).  
By contrast, despite a mild increase in AKT phosphorylation (Supplementary Figure 
S6), the levels of nuclear FOXO3A were not altered in mutant HSCs from the same 
mice ((HSCs: CD150+CD48-EPCR+CD45+),35 Figure 6B)).  
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To confirm this finding in MPN patients, we isolated HSC-enriched population (HSCs; 
Lin-CD34+CD38-CD45RA-CD90+) and more mature progenitors (Lin-CD34+CD38+) 
from JAK2V617F-negative and JAK2V617F-positive patients with very high mutant 
allele burden. Nuclear levels of FOXO3A were reduced in more mature progenitors 
from JAK2 mutant patients compared to those from JAK2 wild-type MPN patients 
(Figure 6C). However, in HSCs isolated from the same patients nuclear localization 
of FOXO3A was not altered by JAK2 genotypes (Figure 6D). Taken together, these 
results demonstrate that mutant JAK2 regulates nuclear localization of FOXO3A 
differently in primitive stem and progenitor cells, compared to more mature cells, with 
the latter showing a marked increase in the cytoplasmic sequestration of FOXO3A. 
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DISCUSSION 
 
JAK2V617F has previously been shown to increase the rate of DNA damage16-19,36 
and to inhibit DNA damage-induced apoptosis by repressing NHE-1 upregulation and 
Bcl-xL deamidation.20,21 These attributes combine to provide a potent mechanism for 
the accumulation of DNA damage thought to drive the progression of JAK2-mutated 
MPNs. However, the mechanism whereby JAK2V617F blocks NHE-1 upregulation 
has remained unknown. In this paper we demonstrate that JAK2V617F results in 
elevated intracellular ROS levels, which in turn inhibit the NHE-1/Bcl-xL pathway in 
response to DNA damage, thereby promoting cell survival.  In addition, we show that 
the increased ROS levels associated with JAK2V617F reflect aberrant PI3K 
signalling and cytoplasmic sequestration of FOXO3A with consequent 
downregulation of catalase expression. However, FOXO3A nuclear localization is 
differentially modulated in more primitive haematopoietic stem and progenitor 
population. 
 
Our data provides a mechanistic link between JAK2V617F and the inappropriate 
survival of cells harboring DNA damage (Figure 7).  It is not clear how increased 
ROS levels repress NHE-1 expression, but one possibility is that a persistent pro-
oxidative state, created by high ROS levels, inactivates the AP2 transcription factor, 
implicated in controlling NHE-1 expression,24-26 by modifying a thiol moiety in AP2 
and thus inhibiting its DNA binding activity.37  Our data do not exclude the possibility 
that repression of pro-apoptotic genes by FOXO3A inactivation also contribute to 
resistance to DNA damage induced apoptosis.  FOXO3A inactivation was reported to 
result in a transcriptional repression of pro-apoptotic BIM.29  Nevertheless, our data 
do demonstrate that increased catalase expression and a reduction in ROS sensitize 
cells to apoptosis in the presence of DNA damage. 
 
The JAK2V617F mutation causes cytokine-independent activation of downstream 
signalling including the PI3K pathway32-34; however, the contribution of activated PI3K 
signalling to MPN pathogenesis is unclear. Previously, PI3K signalling has been 
shown to inactivate FOXO3A,28,31,38 the main FOXO protein operating in 
hematopoietic cells.3,4,39  We demonstrate that JAK2 mutations compromise FOXO3A 
function by PI3K-dependent cytoplasmic sequestration in hematopoietic progenitors 
and clonally-derived erythroblasts isolated from MPN patients as well as in cell lines. 
In addition, we show that JAK2V617F-induced inactivation of FOXO3A leads to 
reduced expression of catalase and, as a result, accumulation of intracellular ROS.   
 11 
Consistent with our findings, Jak2V617F knock-in mice were shown to have reduced 
catalase level and elevated ROS.40  However it remains possible that increased ROS 
in JAK2V617F positive cells may also be regulated by other pathways in addition to 
PI3K/FOXO3A. 
 
Reactive oxygen species function as a “double-edged sword” and the association of 
ROS with cancer is both complex and paradoxical.  While high levels of ROS that 
exceed the antioxidant capacity of the cell could trigger cell death, a moderate 
increase of ROS may promote cell survival.  ROS levels are increased in many types 
of cancer cells and are associated with increased cell survival.41  Our data demonstrate 
that reduction of ROS sensitise cells to apoptosis in response to DNA damage.  
Consistent with our finding, Lin et al reported that antioxidant dihydromyricetin 
reduced ROS and promoted HepG2 cell apoptosis in a concentration-dependent 
manner.42  In addition, ROS are known to result in intrinsic DNA damage; increased	  
DNA	  damage	  has	  previously	  been	  shown	  in	  cells	   from	  the	  JAK2V617F	  knockin	  mice	  
and	  MPN	  patients	  and	  in	  cell	  lines	  expressing	  JAK2V617F.16-­‐19,43	  	  These data indicate 
that the JAK2V617F-mediated increase in ROS plays a dual role in promoting cell 
survival as well as accumulation of DNA damage.  Furthermore, JAK2V617F has 
been reported to facilitate mutagenic DNA repair pathways,44 which, together with 
elevated ROS, would potentiate genome instability and disease progression.  Indeed, 
5-30% of MPN patients can progress to leukemia that is associated with additional 
mutations in genes such as TET2, DNMT3A, and ASXL1.45   
 
Our findings therefore raise the possibility that JAK2V617F-mediated dysregulation of 
FOXO3A is critical in the pathogenesis of human MPNs. In accord with these data, 
FOXO3A-/- mice were reported to exhibit a myeloproliferative phenotype30.  Our 
results also shed light on whether dysregulation of FOXO3A and increased ROS 
levels represent early or late events during tumorigenesis. MPNs are detected early, 
frequently following an incidental blood count, and provide a window on the earliest 
stages of malignancy that are inaccessible in most cancers.  In particular, MPNs 
have not needed to acquire mutations associated with many aspects of the malignant 
phenotype (e.g. differentiation block, tissue invasion, growth in hypoxic environment). 
Our data therefore indicate that FOXO3A inactivation occurs early in the evolution of 
myeloid malignancies, an observation with implications for other cancers in which 
FOXO proteins are dysregulated.6  
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Our findings have several therapeutic implications for the treatment of MPNs and 
other malignancies. The addition of PI3K inhibitors significantly reduces the survival 
of JAK2V617F-positive cells following DNA damage, and reverses the altered ROS 
levels and FOXO3A localization. These data indicate that the PI3K pathway is critical 
for maintaining resistance to apoptosis in malignant cells. Furthermore, we found that 
counteracting the JAK2V617F-induced increase in ROS sensitizes the JAK2-mutant 
cells to a DNA damage-inducing agent. This is reminiscent of findings from other 
cancers where the combination of an antioxidant with chemotherapeutic interventions 
has been shown to be effective in killing drug-resistant tumours.11-13  Malignant cells 
therefore seem to be sensitive to perturbation of the oncogene-mediated altered 
redox state, suggesting that these cells have adapted to and become dependent on 
increased ROS. Since increased activation of the PI3K pathway and elevated ROS 
levels are features common to many cancers, these findings may be relevant well 
beyond hematological malignancies. 
 
FOXO3A inactivation has been previously reported in other haematological 
malignancies such as BCR-ABL positive chronic myeloid leukemia (CML).  Similar to 
JAK2V617F, BCR-ABL activates PI3K pathway which in turn inactivate FOXO3A.28,46 
BCR-ABL specific tyrosine kinase inhibitors (TKI) treatment led to rapid cytogenetic 
response in the majority of CML patients in chronic phase,47 and this is associated 
with FOXO3A reactivation.48 However numerous studies have demonstrated that 
TKIs cannot fully eliminate BCR-ABL transcripts and eradicate disease.49-51 The 
mechanisms for TKI resistance of CML stem and progenitor cells are not entirely 
clear and it has been previously reported that primitive CML cells do not depend on 
BCR-ABL kinase activity for survival.52,53  One line of evidence suggest that the anti-
proliferative effects of TKIs leads to an increase in quiescent CML stem and 
progenitor cells, making them difficult to target.  Importantly, this effect was shown to 
be mediated by FOXO transcription factors.48  Moreover, Naka et al. demonstrated 
that FOXO3A is predominantly localised in the nuclei of CML leukaemia-initiating 
cells (LICs) and that deletion of Foxo3a compromised the ability of LICs to initiate the 
disease in transplant recipients.54  Together, these findings suggest that the function 
of FOXO transcription factors seem to depend largely on the context in which they 
are expressed.  Consistent with this notion, JAK2 inhibitors also fail to eradicate 
primitive HSCs that carry the JAK2V617F mutation55 and previous evidence has 
shown that JAK2V617F has distinct effects on the maintenance and proliferation of 
HSCs compared to progenitors.43 As demonstrated in this study, FOXO3A is mainly 
localised in the nuclei of JAK2V617F-positive primitive HSCs.  Nuclear FOXO3A in 
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mutant HSCs from MPN patients could potentially be responsible for drug 
resistance,55 maintenance of quiescence,5 and/or alternatively, induction of protective 
autophagy under conditions of stress,56 or efficient DNA repair possibly by interacting 
with ATM.57  Thus our data suggest that MPN HSCs may be resistant to cellular 
stress in a Foxo-dependent manner.  Patients with chronic phase MPNs lead normal 
lives, whereas accelerated phase disease is associated with a marked increase in 
morbidity and mortality. Prevention of disease evolution is therefore important and 
this study suggests that combinational therapies specific to HSCs together with JAK2 
inhibitors are required to effectively eradicate the disease.   
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MATERIALS AND METHODS 
 
Reagents 
AT9283 and TG101209 were synthesized at Astex Therapeutics (Cambridge, UK). 
LY294002 was purchased from Cell Signaling (Hitchin, UK) and PI103 from 
Symansis (Buckingham, UK). MitoQ was kindly provided by Michael Murphy (MRC 
Mitochondrial Biology Unit, Cambridge, UK). All other reagents were purchased from 
Sigma (Poole, UK) unless otherwise stated. 
 
Cell lines 
HEL cells were cultured in RPMI supplemented with 10% fetal calf serum. HEL cells 
were treated with DMSO, 1 µM AT9283, or 3 µM TG101209 for 4 hours for 
JAK2V617F inhibition.  Ba/F3-EpoR cells expressing wild-type or mutant JAK2 were 
maintained in RPMI with 10% fetal calf serum, 1 U/ml erythropoietin (R&D Systems, 
Abingdon, UK), and 0.5 mg/ml G418.  
  
Mice 
JAK2V617F knock-in mice were previously generated and reported.22  All mice were 
kept in specific pathogen free conditions and all procedures were performed 
according to rules of the Animal Welfare and Ethical Review Body (AWERB) and the 
UK Home Office regulations. 
 
MPN Patients 
MPN patients diagnosed with either essential thrombocythaemia or polycythaemia 
vera according to the World Health Organisation (WHO) criteria58 were recruited from 
the MPN clinic at the Addenbrooke's Hospital in Cambridge, UK. Informed consent 
was given from all patient subjects. The work involving patient samples was 
approved by the Cambridge and Eastern Region Ethics Committee and was 
performed in accordance with the principles of the Declaration of Helsinki.  
 
Analysis of BFU-E colonies 
Venous blood samples (40 ml) were collected from each patient and peripheral blood 
mononuclear cells (PBMCs) were isolated using Lymphoprep (Axis Shield, Kimbolton, 
UK) according to the manufacturer's instructions. PBMCs (3×105 cells/ml) were then 
plated in methocult (H4531; Stem Cell Technologies, Grenoble, France) 
supplemented with 0.01 U/ml erythropoietin and cultured for 14 days at 37°C. 
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Individual BFU-E colonies were then plucked and resuspended in 30 µl PBS, of 
which 2 µl were used for genotyping by real-time qPCR to determine the JAK2 
mutational status.59 Colonies with JAK2V617F percentages of less than 10% were 
designated "wild-type", those between 40-60% "heterozygous", and those greater 
than 90% "homozygous".  
 
Stem and progenitor cell isolation from MPN patients  
PBMCs from MPN patients were washed with PBS supplemented with 2% fetal 
bovine serum (FBS) and 5mM EDTA and stored overnight at 4ºC in PBS 
supplemented with 10% FBS and 5mM EDTA.  Cells were then washed with PBS 
with 2% FBS and 5mM EDTA and spun at 300g for 7 minutes and the resulting 
pellets were treated with 50uL of 1mg/mL DNase I solution (STEMCELL 
Technologies) to avoid clumping.  Cells were then depleted of differentiated 
hematopoietic cells using the EasySep Human Hematopoietic Progenitor enrichment 
kit (STEMCELL Technologies) with the following modifications:  All samples were 
processed in 500 µl of recommended medium for the first step, the progenitor 
enrichment cocktail was used at 5 µl/mL cells, and the sample was only taken 
through one round of separation.  Cells were then stained with antibodies to isolate 
the various progenitor compartments: anti-CD34 Per-CpCy5.5 (clone 581 Biolegend), 
anti-CD38 FITC (clone HIT2, BD Biosciences), anti-CD90 APC (clone 5E10, BD 
Biosciences), anti-FLK2 PE (clone BV10A4H2, Biolegend), anti-CD10 APC-Cy7 
(clone HI10a, Biolegend), and anti-CD45RA Horizon V450 (HI100, BD Biosciences).  
HSCs were isolated as Lin-CD34+CD38-CD45RA-CD90+, progenitors as Lin-
CD34+CD38+.  Cells were sorted using a BD Influx sorter into tubes containing PBS 
supplemented with 10% FBS and EDTA. 
 
JAK2 knockdown 
HEL cells were transfected with either human JAK2 ON-TARGETplus SMARTpool or 
ON-TARGETplus Non-targeting Pool (control) (Dharmacon RNAi Technologies, UK).  
In detail, 5ul 20uM RNAi (either JAK2 or control) was mixed in 500uL opti-mem 
(Invitrogen, Paisley, UK) in tube A, and 5ul Lipofectamine was mixed in 500ul opti-
mem (Invitrogen) in tube B.  Both tubes were incubated at room temperature for 10 
mins.  Then the mixture of tube A and B were combined and incubated at room 
temperature for 30mins and added to 2mL HEL cells (1 x 106 cells in 6 well plate).  
Cells were collected 48 hours later for analysis. 	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Transfection and retroviral transduction 
MSCV-neo based retroviral vectors MSCV-JAK2(WT)-neo, MSCV-JAK2V617F-neo, 
and MSCV-JAK2K539L-neo were transfected into 293T cells using FuGENE 6 
Transfection Reagent (Roche Applied Science, Burgess Hill, UK) and culture 
supernatants were harvested 48 hours later. Viral infection of Ba/F3-EpoR cells was 
done by spinoculation (2000 rpm for 2 hours at 30°C) and the cells were cultured in 
RPMI with 10% fetal calf serum and 1 U/ml erythropoietin. G418 was added 2 days 
after infection to select for the transduced cells.  
 
Immunofluorescence 
Cytospin slides were fixed and permeabilized in 1:1 mixture of methanol and acetone.   
The slides were blocked for one hour at room temperature and then stained 
overnight at 4°C in 0.2% gelatine in PBS using primary antibody against FOXO3A 
(Cell signaling, 2497S, Hitchin, UK). For immunostaining of pAKT (Cell signalling, 
4060S), the slides were blocked for one hour at room temperature in PBS / 5% 
normal serum / 0.3% Triton™ X-100) and then stained overnight at 4°C in PBS / 1% 
BSA / 0.3% Triton X-100.   The secondary Alexa Fluor® 555-conjugated antibody 
(Life technologies, A-21428) was stained at room temperature for 1 hour in the 
respective primary antibody staining buffer. Nuclei were stained with 4', 6-diamidino-
2-phenylindole (DAPI) (Vectashield, Burlingame, USA) and images were captured 
and scored blindly using ZEISS Axioskop2 mot plus fluorescence microscope 
equipped with a 40× Plan NEOFLUAR lens and an AxioCam MRm camera. Images 
were analysed using Isis software (Oxford Isis, Oxford, UK). 
 
Real-time quantitative PCR 
RNA was extracted using Tri reagent (Sigma) and real-time quantitative PCR was 
performed for human NHE-1 expression using qPCR SYBR Green (Agilent 
Technologies UK Ltd., Workingham, UK) and Mx3000PTM Real-Time PCR system 
(Stratagene). The forward and reverse primers were 5ʹ′-
TTGTTTTTGGGGAGTCCTTG-3ʹ′ and 5ʹ′-ATGCCCACGTGTTCGTAGTT-3ʹ′. Results 
were calculated using the delta-delta-Ct method with ABL as a control.  The forward 
and reverse primers for ABL are 5ʹ′-GCGTGAGAGTGAGAGCAG-3ʹ′ and 5ʹ′-
TCTCGGAGGAGACGTAG-3ʹ′.  NHE1 expression in each sample was normalised to 
ABL expression and the relative NHE1 expression in bar graph represents the 
relative levels to the pZeo-SV2(+) DMSO control which was normalized to 1.	  	   
 17 
Analyses of ROS and apoptosis 
For ROS measurement, cells were stained with 10 µM 2',7'-
dichlorodihydrofluorescein diacetate (H2DCF-DA, Invitrogen).   For Ba/F3-EpoR cells, 
cells were stained with 5 µM dihydrorhodamine 6G (Invitrogen) for 30-45 minutes at 
37°C. Cells were then washed in PBS and the fluorescent signals were analyzed by 
FACS. To analyze apoptosis, cells were stained with Annexin V antibody (Biolegend) 
and 7-Aminoactinomycin D (7-AAD, Invitrogen) in Annexin V binding buffer (BD 
Biosciences).   
 
Western blot analyses 
Western blots on total cell lysates were performed using the following antibodies: 
anti-FOXO3A (Cell Signaling, 2497S), phospho-FOXO3A (Ser319) (Cell Signaling, 
9466S), STAT5 (Santa Cruz, SC-835), phospho-STAT5 (Tyr694) (Cell Signaling, 
9351S), Catalase (Abcam, ab16731), Bcl-xL (BD Biosciences, 610212), anti-SOD2 
(Life Technologies, MA1-106), anti-Glutathione reductase (Abcam, ab128933), β-
actin (Sigma, A2228) and α-Tubulin (Sigma, T9026).   
 
FACS sorting of mouse HSCs and progenitor populations 
Mouse HSCs and progenitors were obtained from JAK2V617F knock-in mice22 and 
their littermate controls (8-10 weeks old, age and sex matched mice in C57BL/6 
background) by FACS sorting of bone marrow MNCs.  E-SLAM HSCs were isolated 
as previously described43 with HSCs as CD150+CD48-EPCR+CD45+ and mature 
progenitors as CD150-CD48+CD45+.   
 
Statistics 
The statistical significance was determined by a 2-tailed, unpaired Student t-test.  
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FIGURE LEGENDS 
 
Figure 1. JAK2V617F elevates intracellular ROS levels and increases survival 
following DNA damage.  (A) JAK2V617F expression increase intracellular ROS in 
Ba/F3-EpoR cells.  A representative flow cytometry histogram is shown and the bar 
graph shows mean fluorescence intensity (MFI) relative to that of the wild-type. (B) 
Knockdown of JAK2V617F reduces ROS in HEL cells. A representative flow 
cytometry histogram is shown and the bar graph shows DCF-DA MFI relative to that 
of the wild-type. (C) JAK2V617F expression in Ba/F3-EpoR cells increase cell 
survival following DNA damage. A representative flow cytometry plot is shown and 
the bar graph shows % of apoptotic cells.  (D) Knockdown of JAK2V617F sensitizes 
cells to DNA damage-induced apoptosis. A representative flow cytometry plot is 
shown and the bar graph shows % of apoptotic cells.  All data are averages of three 
independent experiments and shown as mean ± SEM.  **P<0.01 and *** P<0.001. 
 
Figure 2. Elevation of ROS levels by JAK2V617F increases resistance to DNA 
damage-induced apoptosis.  (A) MitoQ treatment reduced ROS levels in HEL cells. 
Fold decrease in ROS levels following MitoQ treatment relative to the untreated 
culture is shown. (B) Reduced ROS restored sensitivity to DNA damage induced 
apoptosis in HEL cells. (C) Western blot shows Catalase expression in HEL cells 
transfected with an empty pZeo-SV2(+) or catalase expression construct pZeo-CAT.  
(D) Catalase expression in HEL cells (pZeo-CAT) reduced ROS levels. The bar 
graph shows mean fluorescence intensity relative to that of the wild-type. (E) 
Reduction of ROS levels increased apoptosis in the presence of DNA damage. (F) 
Reduction in ROS levels allows NHE-1 upregulation in HEL cells in response to DNA 
damage. (G) ROS reduction allows Bcl-xL deamidation in HEL cells in the presence 
of DNA damage. The upper bands (deamidated) and lower bands (native) were 
quantified using the Image J software and the deamidated protein was quantified as 
a percentage of total Bcl-xL.  Data are shown as mean ± SEM; n=3. *P<0.05, 
**P<0.01 and *** P<0.001. 
 
Figure 3. JAK2V617F reduces nuclear localization of FOXO3A. (A) JAK2 
inhibitors increased the expression of catalase in HEL cells. (B) JAK2V617F 
knockdown in HEL cells increased the expression of catalase. (C) Catalase 
expression was reduced in Ba/F3-EpoR cells carrying Jak2V617F compared to 
wildtype Jak2. (D) JAK2V61F knockdown induced nuclear localization of FOXO3A. 
Representaive images are shown.  Nuclear FOXO3A is shown as a percentage of 
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total FOXO3A. Numbers in parentheses indicate the numbers of cells analyzed for 
each samples. (E) Jak2V617F expression in BaF/3-EpoR cells increased cytoplasmic 
sequestration of FOXO3A compared to the wild-type.  Data are mean ± SEM. 
***P<0.001. 
 
Figure 4. Inactivation of FOXO3A is mediated by the PI3K signaling pathway. 
(A) Treatment with PI3K inhibitors relocalize FOXO3A to the nucleus in HEL cells. 
Representative pictures are shown on the left. Percentage of nuclear FOXO3A is 
shown on the right as an average of minimum 45 cells. (B) Western blot shows 
inhibition of PI3K increased in catalase expression. (C) Inhibition of PI3K reduced 
ROS levels.  (D, E) Inhibition of PI3K increased the sensitivity of HEL cells to DNA 
damage-induced apoptosis and catalase inhibitor, sodium azide, reversed the 
sensitivity to apoptosis in response to DNA damage.  All results are averages of 
three independent experiments and shown as mean ± SEM. *P<0.05, **P<0.005 and 
***P<0.0005. 
 
Figure 5. JAK2V617F induces increased cytoplasmic sequestration of FOXO3A 
in erythroblasts from MPN patients. (A) JAK2V617F causes increased cytoplasmic 
sequestration of FOXO3A in BFU-E colonies derived from MPN patients. 
Representative images are shown.  (B) Reduced FOXO3A nuclear localization in 
cells carrying JAK2V617F compared to the cells with normal JAK2. Graph shows the 
data obtained from each patient (Patient 1: ET, heterozygous for JAK2V617F; Patient 
2: PV, heterozygous for JAK2V617F; Patient 3: PV, both heterozygous and 
homozygous BFU-E clones for JAK2V617F). Numbers in parentheses indicate the 
numbers of cells analyzed for each samples. Data are mean ± SEM.  **P<0.005, 
***P<0.0005.  (C) Mutant BFU-E colonies show increased ROS levels compared to 
the wild-type colonies. BFU-E colonies from five MPN patients were stained with 
DCF-DA. The data were normalised (WT=1) and relative fold increase is shown.	   	  A 
representative flow cytometry histogram is shown on the right. **P<0.005. 
 
Figure 6. Mutant JAK2-FOXO3A signaling is different in stem cells compared to 
the progenitors. (A) JAK2V617F induces an increase in the cytoplasmic 
sequestration of FOXO3A in the hematopoietic progenitors of JAK2V617F knock-in 
mice. (B) FOXO3A nuclear localisation is not altered in the nuclei of primitive HSCs 
in both wild-type and JAK2V617F-positive mice. Representative images are shown in 
the left panel and bar graphs show the mean percentages of nuclear FOXO3A in the 
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right panel.  Numbers in parentheses indicate the numbers of cells analyzed from 
each mouse.  (C) JAK2V617F induces an increase in the cytoplasmic sequestration 
of FOXO3A in the hematopoietic progenitors of MPN patients. WT1 and WT2: 
JAK2V617F-negative patients; VF1, VF2 and VF3: JAK2V617F-positive patients. 
Numbers in brackets indicate numbers of cells analyzed from each patient. (D) 
FOXO3A is in the nuclei of primitive HSCs in both JAK2V617F-negative and -positive 
patients.  Data are mean ± SEM. ***P<0.0005. 
 
Figure 7. Schematic pathway of JAK2V617F inhibition of the NHE-1/Bcl-xL 
regulated apoptosis. Upper panel shows a normal signaling pathway of apoptosis in 
response to DNA damage. Lower panel shows the dysregulated pathway in the 
JAK2V617F positive cells.  Dashed lines illustrate other unidentified factors or 
pathways that may potentially regulate ROS and resistance to DNA damage induced 
apoptosis in JAK2V617F positive cells. 
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